Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.7 million.

  • Enanta Pharmaceuticals' Profit After Tax rose 3512.13% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.9 million, marking a year-over-year increase of 2943.34%. This contributed to the annual value of -$81.9 million for FY2025, which is 2943.34% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Profit After Tax stood at -$18.7 million for Q3 2025, which was up 3512.13% from -$18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Profit After Tax high stood at -$18.3 million for Q2 2025, and its period low was -$39.1 million during Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median Profit After Tax value was -$28.1 million (recorded in 2023), while the average stood at -$27.6 million.
  • In the last 5 years, Enanta Pharmaceuticals' Profit After Tax tumbled by 26711.07% in 2021 and then surged by 4199.92% in 2024.
  • Enanta Pharmaceuticals' Profit After Tax (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then rose by 16.11% to -$18.7 million in 2025.
  • Its Profit After Tax was -$18.7 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.